Skip to main content
OpenTrials
Completed

NCT Number: NCT05320991

Effects of Ketamine on Mentalizing and Metacognition in Healthy Volunteers

Antipsychotic medication shows generally good effect sizes when looking at reduction of positive psychotic symptoms of schizophrenia, such as paranoia or delusion. However, social functioning often remains deficient in patients, meaning dopamine-receptor antagonists are not sufficient in treatment of people with schizophrenia.

A naturalistic video-based paradigm, named MASC has been used in the past to model over- and undermentalizing in patients with autism spectrum disorder and schizophrenia, since deficits in mentalizing can be explained by either overinterpreting a social situation (e.g. paranoid thoughts about intentions of others towards self) or by lacking the skill to read intentions of others.

To find out whether experimental manipulation via a non-competetive N-methyl-D-aspartate antagonist can induce difficulties with social cognition similar to those observed in people with schizophrenia, the investigators will conduct a RCT applying either ketamine or a placebo intravenously while participants are completing the above mentioned mentalizing task in the fMRI-scanner.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Ketamine-Induced Psychotic Disorder Mental Disorders Psychotic Disorders Schizophrenia Spectrum and Other Psychotic Disorders Social Cognition Theory of Mind

Age range

18 year–35 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Department of Psychiatry and Psychotherapy, University Hospital Bonn

Bonn, 53127, Germany

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Potential participants are excluded based on the following criteria:

  • history of psychiatric/neurological disorder (self and first-degree relatives)
  • learning disabilities, or loss of consciousness for more than 5 minutes
  • history of alcohol or drug abuse within the last 12 months
  • history of ketamine abuse
  • history of complications during anesthesia (self and first-degree relatives)
  • serious physical illness
  • claustrophobia
  • color-blindness
  • metalliferous implant
  • visual impairments other than corrective lenses
  • injury or disease of the inner ear with loss of hearing
  • consumption of any prescription or over-the-counter medication 3 days previous to the examination
  • pregnancy
  • currently breastfeeding a baby
  • hypotension (blood pressure < 100/60)
  • hypertension (blood pressure > 140/90)
  • underweight (BMI <17)
  • overweight (BMI ≥30)

Recruited participants are required to meet the following criteria:

  • height between 150 and 195 cm
  • bodyweight between 50 and 99kg
  • male or female
  • right-handed
  • physically, neurologically and psychiatrically healthy
  • non-smoker
  • normal or corrected-to-normal eye-sight
  • good command of German language

Treatment and study plan

ketamine

Drug

Ketamine is applied with a Graseby 3500 intravenous infusion pump controlled by the STANPUMP software (Steven Shafer, M.D., Anesthesiology Service, PAVAMC 3801 Miranda Ave., Palo Alto, USA). Target plasma levels are 100 ng/ml with an initial bolus administered as a 2 mg/ml solution.

NaCl 0.9%

Drug

Saline solution will also be applied with the Graseby 3500 intravenous infusion pump controlled by the STANPUMP software (Steven Shafer, M.D., Anesthesiology Service, PAVAMC 3801 Miranda Ave., Palo Alto, USA).

Primary outcomes

  1. Changes in Mentalizing/Theory of Mind

    Time frame: During ketamine/placebo application in MRI

    Over- and undermentalizing as characterized by the Movie for the assessment of social cognition (MASC). Higher scores on the "Mentalizing"-scale indicate better performance. Scores are divded between 4 scales (Mentalizing, No Mentalizing, Overmentalizing, Undermentalizing), each ranging from 0 to 27. Higher scores in one of the scales pertaining to "no Mentalizing, Overmentalizing or Undermentalizing mean a deficiency in mentalizing skills.

  2. Neural response to ketamine/placebo during social cognition

    Time frame: During ketamine/placebo application in MRI

    fMRI imaging will be performed to measure blood oxygen level-dependent (BOLD) signal in response to mentalizing cues in the MASC-task under ketamine/placebo. BOLD-signal will be measured with T2-weighted images in a 3T MRI. Data will be analyzed using SPM 12 in MATLAB. Deviations in BOLD-activity under ketamine compared to placebo (higher or lower activity of certain voxels/clusters compared all other voxels in the brain) will mean a change in neural response due to the effect of the substance

Secondary outcomes

  1. Psychotic symptom load in PANSS-Questionnaire

    Time frame: 10 minutes after cessation of MRI and ketamine/placebo application

    Positive and negative symptoms measured with questionnaire used in schizophrenia-research (Positive and Negative Symptom Scale). The PANSS uses a scale ranging from 1 to 7 in three different subscales (positive, 7 items; negative, 7 items; disorganized, 16 items). Higher numbers mean more psychotic symptoms.

  2. Metacognitive-Questionnaire (MCQ)

    Time frame: 20 minutes after cessation of MRI and ketamine/placebo application

    Metacognitive typology as assessed with the MCQ. The MCQ is a questionnaire containing 30 items, based on a 4-point Likert scale (dont agree - strongly agree) from 1 to 4. It measures metacognitive ability in 5 subscales, each containing 6 items (Uncontrollability and Danger, Cognitive Self-Consciousness, Need to control thoughts, Positive Beliefs, Cognitive Confidence). This is a short form of the widely used Metacognitions Questionnaire that measures individual differences in a selection of metacognitive judgments and monitoring tendencies considered important in the metacognitive model of psychological disorders

Sponsors and collaborators

Lead sponsor

University Hospital, Bonn

Other

Registry information

Official study title

A Randomized Control Trial Employing fMRI to Investigate the Effects of Ketamine on Mentalizing and Metacognition in Healthy Volunteers

Acronym: METAKETAII

Important dates

Study start
2019
Primary completion
2020
Study completion
2020
First posted
Apr 11, 2022
Registry last updated
Apr 18, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.